UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
|
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Delaware
(State or Other Jurisdiction
of Incorporation)
|
002-90539
(Commission File Number)
|
59-2262718
(IRS Employer
Identification No.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 40.14d - (b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e - (c))
|
In addition, on August 14, 2013, the Company exercised its option and converted the Series B Convertible Preferred Stock (“Series B Preferred”), held by Crede into 42,307,692 shares of the Company’s Common Stock at a conversion price of $0.13 per share. On July 31, 2013, the second closing of our transaction with Crede occurred at which Crede purchased 5,500 shares of Series B Preferred at a price of $1,000 per share with gross proceeds received by us of $5,500,000, as previously disclosed on the Current Report on Form 8-K filed by the Company on August 1, 2013.
Applied DNA Sciences, Inc.
|
||
(Registrant)
|
||
By:
|
/s/ James A.
Hayward James A. Hayward
Chief Executive Officer
|
|
Date:August 15, 2013
|
||